Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: safety and proof of mechanism
Authors
Lolkema, MPPlummer, ER
De Vos, FYFL
Forster, MD
Angevin, E
Libouban, M
Jansen, E
Tjwa, M
Ciamporcero, E
Meulemans, A
Van der Aa, A
Perera, TPS
Clack, G
Krebs, Matthew G
Blagden, SP
Affiliation
University Medical Center Utrecht, Utrecht, NetherlandsIssue Date
2019
Metadata
Show full item recordCitation
Lolkema MP, Plummer ER, De Vos FYFL, Forster MD, Angevin E, Libouban M, et al. Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: safety and proof of mechanism. J Clin Oncol. 2019;37(15_suppl):3062-.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2019.37.15_suppl.3062Additional Links
https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.3062Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2019.37.15_suppl.3062